Capricor Therapeutics, Inc.CAPR
ASignal's systematic analysis rates CAPR as Neutral.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on CAPR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with total cash of $237.93M
- Low debt-to-equity ratio of 0.37x indicating conservative leverage
- High current and quick ratios (7.35x and 7.22x) suggesting solid short-term financial health
- PEG ratio of 0.38x indicates potential undervaluation relative to growth
- Negative return on equity (-73.70%) and return on assets (-33.63%)
- Zero gross, operating, and net margins indicating lack of profitability
- Negative free cash flow (-$89.19M) and operating cash flow (-$104M)
- Overbought RSI at 76.57 suggesting potential price reversal risk
- MACD below signal line despite positive histogram, indicating weakening momentum
See the full verdict on CAPR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CAPR
Most investors never get a second opinion, let alone several. ASignal runs CAPR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.